Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,264,960
  • Shares Outstanding, K 74,543
  • Annual Sales, $ 301,030 K
  • Annual Income, $ -361,920 K
  • 60-Month Beta 2.19
  • Price/Sales 24.12
  • Price/Cash Flow N/A
  • Price/Book 6.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.81
  • Number of Estimates 9
  • High Estimate -1.66
  • Low Estimate -1.95
  • Prior Year -2.05
  • Growth Rate Est. (year over year) +11.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.43 +19.69%
on 10/31/19
103.44 -5.78%
on 11/13/19
+9.41 (+10.69%)
since 10/15/19
3-Month
72.05 +35.27%
on 09/26/19
126.71 -23.08%
on 08/19/19
-24.51 (-20.10%)
since 08/15/19
52-Week
72.05 +35.27%
on 09/26/19
158.80 -38.63%
on 07/15/19
-21.50 (-18.07%)
since 11/15/18

Most Recent Stories

More News
Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal

Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.

AVEO : 0.63 (-1.96%)
SRPT : 97.46 (+0.05%)
ALKS : 21.00 (+5.37%)
ANIK : 60.01 (+0.40%)
Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies

-- Agreement leverages StrideBio's novel, industry-leading, structure-driven capsid engineering platform and expands Sarepta's early stage gene therapy pipeline -

SRPT : 97.46 (+0.05%)
Look for Shares of Sarepta Therapeu to Potentially Pullback after Yesterday's 10.20% Rise

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $93.52 to a high of $96.00. Yesterday, the shares gained 10.2%, which took the trading range above the 3-day high...

SRPT : 97.46 (+0.05%)
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.

SRPT : 97.46 (+0.05%)
BMRN : 75.04 (-0.71%)
ALKS : 21.00 (+5.37%)
VRTX : 209.80 (+2.34%)
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -26.87% and 1.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

SRPT : 97.46 (+0.05%)
Sarepta Therapeutics: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Thursday reported a loss of $126.3 million in its third quarter.

SRPT : 97.46 (+0.05%)
Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2019.

SRPT : 97.46 (+0.05%)
Sarepta Therapeu Has Returned 6.8% Since SmarTrend Recommendation (SRPT)

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on October 4th, 2019 at $87.38. In approximately 1 month, Sarepta Therapeu has returned 6.76% as of today's recent price of $93.28.

SRPT : 97.46 (+0.05%)
Sarepta Therapeu Rises 8.84% on Heavy Volume: Watch For Potential Pullback

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $91.83 to a high of $94.51. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high...

SRPT : 97.46 (+0.05%)
Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Credit Suisse 28 Annual Healthcare Conference...

SRPT : 97.46 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade SRPT with:

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

2nd Resistance Point 99.33
1st Resistance Point 98.39
Last Price 97.46
1st Support Level 96.56
2nd Support Level 95.67

See More

52-Week High 158.80
Fibonacci 61.8% 125.66
Fibonacci 50% 115.43
Fibonacci 38.2% 105.19
Last Price 97.46
52-Week Low 72.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar